Reports >
Life Sciences
>
Asthma And Copd Devices Market Report
Asthma And Copd Devices Market Report
First published: 15 October 2024 | Last updated: 22 April 2026 | Report Code: asthma-and-copd-devices
Asthma And Copd Devices Market — USD 10.5 billion in 2023, Growing to USD 18.70B by 2033 at 5.8% CAGR
This report provides a comprehensive analysis of the Asthma and COPD devices market, including insights on market size, growth forecasts, trends, and regional performances from 2023 to 2033.
Key Takeaways
- The market was $10.50 Billion in 2023 and is expected to reach $18.70 Billion by 2033, reflecting a 5.8% CAGR over the forecast period.
- North America is both the largest and the fastest-growing region, driven by strong clinical adoption and advanced device platforms.
- Product categories such as inhalers, spacers and monitoring devices remain central, with digital device uptake accelerating market transformation.
- Leading pharmaceutical and device firms—GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Novartis—are prominent in development and commercialization.
- Regional expansion in Europe and Asia Pacific supports sustained demand, while distribution channels including pharmacies, online stores and hospitals continue to expand reach.
Asthma And Copd Devices Market Report — Executive Summary
The report outlines an industry expanding from $10.50 Billion in 2023 to $18.70 Billion by 2033, at a 5.8% CAGR during 2023 to 2033. Growth is supported by rising clinical need, advances in connected and digital devices, and broader distribution through retail, online and institutional channels. North America stands out as the largest market and the fastest-growing region, reflecting strong technology adoption and healthcare investment. The analysis covers device types including inhalers, spacers and monitoring devices, technologies spanning digital and traditional offerings, and end users from hospitals to home patients. Competitive coverage highlights major players such as GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Novartis, with emphasis on innovation, partnerships and regulatory influence. The report integrates primary interviews and secondary data to present trend-led insights useful for product strategy, regional entry and stakeholder planning.
Key Growth Drivers
- Increasing prevalence of respiratory conditions prompting greater device demand and long-term management solutions.
- Adoption of connected and digital devices improving adherence monitoring and remote care capabilities.
- Rising healthcare spending and infrastructure expansion, particularly in developed markets, facilitating device procurement.
- Expanded distribution through retail pharmacies, online stores and institutional channels broadening patient access.
- Product innovation by leading companies driving differentiated offerings and competitive positioning.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $10.50 Billion |
| CAGR (2023-2033) | 5.8% |
| 2033 Market Size | $18.70 Billion |
| Top Companies | GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis |
| Published Date | 15 October 2024 |
| Last Modified Date | 22 April 2026 |
Asthma And Copd Devices Market Overview
Customize Asthma And Copd Devices Market Report market research report
- ✔ Get in-depth analysis of Asthma And Copd Devices market size, growth, and forecasts.
- ✔ Understand Asthma And Copd Devices's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Asthma And Copd Devices
What is the Market Size & CAGR of Asthma And Copd Devices Market Report market in 2023?
Asthma And Copd Devices Industry Analysis
Asthma And Copd Devices Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Asthma And Copd Devices Market Report Market Analysis Report by Region
Europe Asthma And Copd Devices Market Report:
Europe grows from $2.71 Billion in 2023 to $4.83 Billion in 2033. Expansion is supported by established care networks, regulatory frameworks encouraging device innovation, and demand for improved monitoring and adherence solutions across clinical and home settings.Asia Pacific Asthma And Copd Devices Market Report:
Asia Pacific increases from $2.25 Billion in 2023 to $4.01 Billion in 2033. Growth is tied to rising healthcare access, growing awareness of respiratory diseases, and gradual adoption of digital and traditional device offerings across urban and peri-urban centers.North America Asthma And Copd Devices Market Report:
North America is the largest and fastest-growing region, rising from $3.37 Billion in 2023 to $6 Billion in 2033. Regional strength reflects advanced clinical adoption, high healthcare spending, and early uptake of connected device technologies by providers and patients.South America Asthma And Copd Devices Market Report:
Middle East & Africa Asthma And Copd Devices Market Report:
The Middle East and Africa region expands from $1.29 Billion in 2023 to $2.29 Billion in 2033. Drivers include increasing healthcare investment, rising prevalence of respiratory conditions, and growing distribution reach into clinical and home-care environments.Tell us your focus area and get a customized research report.
Research Methodology
Asthma And Copd Devices Market Analysis By Device Type
The Asthma and COPD devices market can be categorized into different device types, including inhalers, nebulizers, monitoring devices, and digital devices. Inhalers dominate the market with a size of 7.23 billion USD in 2023 and projected to reach 12.87 billion USD by 2033, capturing a significant share of 68.83% throughout the years. Meanwhile, nebulizers and digital monitoring devices are gaining traction as patients seek convenient and effective management of their conditions.
Asthma And Copd Devices Market Analysis By Application
The market segmentation by application shows considerable presence in chronic care management and home healthcare settings. Hospital use accounted for around 2.80 billion USD in 2023 and is expected to grow to nearly 4.99 billion USD by 2033, representing a crucial area of focus for device manufacturers. With growing patient consciousness regarding the management of asthma and COPD, the home care segment is anticipated to grow substantially due to its convenience.
Asthma And Copd Devices Market Analysis By End User
Key end-users of asthma and COPD devices include hospitals, clinics, and home patients. Market insights reveal that hospital usage will continue holding a major share at approximately 68.83% by 2033. The rise in telemedicine and at-home monitoring solutions showcases a growing trend towards patient-centric care, offering devices like digital inhalers that facilitate effective self-management.
Asthma And Copd Devices Market Analysis By Technology
The technology landscape in asthma and COPD devices includes a diverse range of products ranging from traditional devices to advanced digital inhalers. Digital devices, generating a market size of 9.25 billion USD in 2023 and expected to reach 16.47 billion USD by 2033, represent an innovative shift towards improved patient engagement and adherence. These advancements also lead to enhanced data collection and improved healthcare outcomes.
Asthma And Copd Devices Market Analysis By Distribution Channel
Distribution channels for asthma and COPD devices encompass hospitals, retail pharmacies, online stores, and clinics. Retail pharmacies are expected to maintain a substantial 68.83% market share, valued at 7.23 billion USD in 2023, while online sales are gradually increasing due to a shift in consumer preferences towards e-commerce platforms for healthcare products.
Asthma And Copd Devices Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Asthma And Copd Devices Industry
GlaxoSmithKline:
A prominent player in the respiratory industry, GlaxoSmithKline specializes in developing innovative inhalers and treatments for asthma and COPD.AstraZeneca:
Known for its research in respiratory diseases, AstraZeneca offers a range of advanced inhalation devices that enhance patient outcomes.Boehringer Ingelheim:
Boehringer Ingelheim focuses on developing inhalation therapies and is recognized for its innovative products in asthma and COPD management.Novartis:
Novartis is engaged in developing treatment solutions for respiratory conditions, enhancing quality of life for asthma and COPD patients.We're grateful to work with incredible clients.
FAQs
What is the market size in 2023?
The market size for asthma and COPD devices was $10.50 Billion in 2023. This serves as the 2023 baseline for projections through the forecast period of 2023 to 2033.
How big will the market be in 2033?
By 2033 the market is forecast to reach $18.70 Billion. This projection reflects growth measured over the 2023 to 2033 horizon under the report's assumptions and trend analysis.
What is CAGR for the forecast period?
The compound annual growth rate for the market is 5.8% for the forecast period 2023 to 2033. This rate summarizes expected average annual expansion across the decade.
Why is North America significant?
North America is identified as the largest and fastest-growing region, benefiting from technology adoption, established healthcare infrastructure and strong engagement from major companies and providers.
Which product types are covered?
The report addresses device types including inhalers, spacers and monitoring devices, reflecting both traditional and digital technology deployments across care settings.
Who are the top companies in the market?
Prominent companies highlighted in the analysis include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Novartis, noted for product development and market presence.
What distribution channels are emphasized?
Key distribution channels covered are retail pharmacies, online stores and hospitals and clinics, each influencing accessibility and reach across patient segments and regions.
How does the report approach research?
The study combines primary interviews, company publications and data triangulation to validate findings and present trend-driven insights for stakeholders and decision makers.